Two hundred thirty cases of malignant non‐Hodgkin's lymphomas were reclassified in a retrospective study according to the New Working Formulation for Clinical Usage of the NCI as compared to the Rappaport and Kiel classifications. The reproducibility for the individual schemes this study was 81% (Rappaport), 79% (Kiel), and 85% (New Working Formulation). In keeping with the results of the NCI international study,1 all lymphomas were subdivided into 3 prognostic groups: (1) low‐grade malignancy (6.0 years median survival); (2) intermediate‐grade malignancy (3.5 years median survival); and (3) high‐grade malignancy (1.4 years median survival). The NCI‐proposed New Working Formulation for Clinical Usage is thus recommended as practical and unprejudicing classification scheme for general application; however, its usefulness as tool for translating one classification scheme into another appears limited.
In four cases of hairy cell leukemia a cytochemical polymorphism concerning acid phosphatase (AP) is evident. Any AP is lacking in all hairy cells of one case; only tartrate inhibitable AP is occurring in two cases, in another case tartrate resistant AP is found in high activity. Thus, the lack of tartrate resistant AP seems not to be an argument against hairy cell leukemia.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.